<DOC>
	<DOCNO>NCT00632749</DOCNO>
	<brief_summary>Investigation maximum tolerate dose , safety , efficacy pharmcokinetics BI 811283 combination cytarabine ( LD-Ara-C ) previously untreated acute myeloid leukaemia ( AML ) patient</brief_summary>
	<brief_title>BI 811283 Combination With Cytarabine Previously Untreated AML Ineligible Intensive Treatment</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Inclusion criterion : Male female adult previously untreated acute myeloid leukaemia ( AML ) Confirmed diagnosis AML accord WHO definition ( except acute promyelocytic leukaemia , APL ) Patient consider ineligible intensive treatment Patient eligible lowdose cytarabine ( LDAraC ) treatment Life expectancy &gt; 3 month Eastern cooperative oncology group ( ECOG , R010787 ) performance score &lt; =2 screen Signed write informed consent consistent international conference harmonisation good clinical practice ( ICHGCP ) local legislation Exclusion criterion : Patient APL ( AML subtype M3 accord FrenchAmericanBritish ( FAB ) classification ) . Relapsed treatment refractory AML . Hypersensitivity one trial drug excipients . Other malignancy require treatment . Known central nervous system involvement . Aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) great 2.5 time upper limit normal ( ULN ) . INR &gt; 1.5 x ULN subject therapeutic vitamin K antagonist ( phenprocoumon , warfarin ) . Bilirubin great 1.5 mg/dl . Serum creatinine great 2.0 mg/dl . LVEF ( Left ventricular ejection fraction ) &lt; 50 % echocardiography clinical congestive heart failure New York Heart Association ( NYHA ) grade III IV . Concomitant intercurrent illness , would compromise evaluation efficacy safety trial drug , e.g . active severe infection , unstable angina pectoris cardiac arrhythmia . Psychiatric illness social situation would limit compliance trial requirement . Concomitant therapy , consider relevant evaluation efficacy safety trial drug ( i.e . chemo immunotherapy , see also section 4.2.2 ) . Contraindications cytarabine treatment accord summary product characteristic ( SPC ) . Patients sexually active unwilling use medically acceptable method contraception trial ( hormonal contraception , intrauterine device , condom spermicide , etc. ) . Pregnant nursing female patient . Patient unable comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>